Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Apr 9;12:1179554918763367. doi: 10.1177/1179554918763367

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2018

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).

PMC Copyright notice

Figure 1. — This image demonstrates the metabolic changes observed on the ¹⁸F-FDG PET/CT at baseline (prior to initiating MS with TMZ in September 2015), restaging studies performed after 5 cycles, in May 2016, and 15 cycles, in March 2017, of the chemotherapy regimen consisting of MS with TMZ and high-dose lanreotide. In September 2015, maximum standardized uptake value (SUV_max) normalized to lean body mass (SUL_max) of the most active lesion (marked in orange) was 23.12. In May 2016, a PMR was noted (SUL_max) of the target lesion = 12.49, which is 45.9% reduction). In March and September 2017, there was stabilization of the PMR and no new lesions were detected on either of the studies. ¹⁸F-FDG PET/CT: ¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography; PMR: partial metabolic response; TMZ: temozolomide.